Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Virology

• Publication date

  2000-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.74.15.7096-7107.2000PMID 10888650PMCID PMC112228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.

  2000cited by this paper
• Mass Spectrometric Characterization of a Discontinuous Epitope of the HIV Envelope Protein HIV-gp120 Recognized by the Human Monoclonal Antibody 1331A1

  2000cited by this paper
• Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41

  2000cited by this paper
• An Unusual HIV Type 1 env Sequence Embedded in a Mosaic Virus from Cameroon: Identification of a New env Clade

  1999cited by this paper
• Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV

  1999cited by this paper
• Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins

  1999cited by this paper
• Both Neutralization Resistance and High Infectivity Phenotypes Are Caused by Mutations of Interacting Residues in the Human Immunodeficiency Virus Type 1 gp41 Leucine Zipper and the gp120 Receptor- and Coreceptor-Binding Domains

  1999cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors*

  1998cited by this paper
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• Identification of a new human immunodeficiency virus type 1 distinct from group M and group O

  1998cited by this paper
• HIV entry and its inhibition.

  1998cited by this paper
• A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-Reacts with Other HIV Type 1 Clades

  1998cited by this paper
• Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage

  1998cited by this paper
• Human Immunodeficiency Virus (HIV) Envelope Binds to CXCR4 Independently of CD4, and Binding Can Be Enhanced by Interaction with Soluble CD4 or by HIV Envelope Deglycosylation

  1998cited by this paper
• Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1

  1998cited by this paper
• A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

  1998cited by this paper
• The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.

  1998influential reference
• Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments.

  1997cited by this paper
• Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein

  1997cited by this paper
• Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

  1997cited by this paper
• High and low efficiency neutralization epitopes on the haemagglutinin of type A influenza virus.

  1997cited by this paper
• The Neutralization Relationship of HIV Type 1, HIV Type 2, and SIVcpz Is Reflected in the Genetic Diversity that Distinguishes Them

  1997cited by this paper
• Prevalence of a V2 epitope in clade B primary isolates and its recognition by sera from HIV-1-infected individuals.

  1997cited by this paper
• Recombinant Human Monoclonal Antibody IgG1b12 Neutralizes Diverse Human Immunodeficiency Virus Type 1 Primary Isolates

  1997cited by this paper
• Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

  1997cited by this paper
• Atomic structure of the ectodomain from HIV-1 gp41

  1997cited by this paper
• Multivariate analysis of human immunodeficiency virus type 1 neutralization data

  1996cited by this paper
• Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein

  1996cited by this paper
• Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I

  1995cited by this paper
• Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

  1995cited by this paper
• Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin

  1995cited by this paper
• Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry

  1995cited by this paper
• Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain

  1995cited by this paper
• Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120

  1995cited by this paper
• Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.

  1995influential reference
• Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

  1995cited by this paper
• Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

  1995cited by this paper
• An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.

  1994cited by this paper
• Genetic and Phylogenetic Analysis of env Subtypes G and H in Central Africa

  1994influential reference
• Genotypic subtypes of HIV‐1 in Cameroon

  1994influential reference
• Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.

  1994cited by this paper
• Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1

  1994cited by this paper
• Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization

  1994cited by this paper
• Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon.

  1994cited by this paper
• Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate

  1994cited by this paper
• A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon

  1994cited by this paper
• Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS

  1994cited by this paper
• Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies

  1994influential reference
• Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

  1994cited by this paper
• Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

  1994cited by this paper
• Phylogenetic analysis of gag genes from 70 international HIV‐1 isolates provides evidence for multiple genotypes

  1993cited by this paper
• A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

  1993cited by this paper
• Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions

  1993cited by this paper
• Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

  1993cited by this paper
• Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

  1993cited by this paper
• Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding

  1993cited by this paper
• Production of Human Monoclonal Antibodies Specific for Conformational and Linear Non-V3 Epitopes of gp120

  1992cited by this paper
• Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

  1992cited by this paper
• Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120.

  1992cited by this paper
• An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection.

  1991cited by this paper
• Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

  1991cited by this paper
• Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies

  1991cited by this paper
• Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.

  1990cited by this paper
• Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

  1990cited by this paper
• Generation of human monoclonal antibodies to human immunodeficiency virus.

  1989cited by this paper
• Human retroviruses and AIDS.

  1988cited by this paper
• Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

  1988cited by this paper
• Human retroviruses and AIDS.

  1988cited by this paper
• Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

  1988cited by this paper
• Quantitative relationships between an influenza virus and neutralizing antibody.

  1987cited by this paper
• Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS

  1986cited by this paper
• Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides

  1983cited by this paper

• Development of a Virus Particle-Based Antibody-Dependent Cellular Phagocytosis (ADCP) Assay for HIV

  2025cites this paper
• Applying Flow Virometry to Study the HIV Envelope Glycoprotein and Differences Across HIV Model Systems

  2024cites this paper
• Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity

  2024cites this paper
• Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells

  2023cites this paper
• Production and immunogenicity assessment of a ToxA-based multiepitope plant-made protein targeting enteric pathogens

  2023cites this paper
• Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers

  2022cites this paper
• Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

  2022cites this paper
• Dual Role of HIV-1 Envelope Signal Peptide in Immune Evasion

  2022cites this paper
• Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis

  2021cites this paper
• Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

  2021cites this paper
• Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine–Induced Anti-V2 Antibodies Alone

  2021cites this paper
• Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes

  2020cites this paper
• Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques

  2020cites this paper
• Signal Peptide of HIV-1 Envelope Modulates Glycosylation Impacting Exposure of V1V2 Epitopes

  2020cites this paper
• Search for antiviral functions of potentially protective antibodies against V2 region of HIV-1

  2020influential citation
• Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

  2019cites this paper
• V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers

  2019cites this paper
• Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes

  2019cites this paper
• Identification of HIV gp41-specific antibodies that mediate killing of infected cells

  2019cites this paper
• Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses.

  2019cites this paper
• Primary Human Neutrophils Exhibit a Unique HIV-Directed Antibody-Dependent Phagocytosis Profile

  2018cites this paper
• Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations

  2018cites this paper
• Optimized protocol for detection of native, full‐length HIV‐1 envelope on the surface of transfected cells

  2018cites this paper
• HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

  2018cites this paper
• Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

  2017cites this paper
• Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer

  2017cites this paper
• Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner

  2017cites this paper
• Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity

  2017cites this paper
• Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240

  2016cites this paper
• Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies

  2016cites this paper
• Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits

  2016cites this paper
• Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies

  2015cites this paper
• Worldwide Genetic Features of HIV-1 Env &agr;4&bgr;7 Binding Motif: The Local Dissemination Impact of the LDI Tripeptide

  2015cites this paper
• Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research

  2015cites this paper
• Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

  2015cites this paper
• A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

  2015cites this paper
• Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

  2014cites this paper
• Transcriptional Profiling of Mycobacterium tuberculosis Replicating Ex vivo in Blood from HIV- and HIV+ Subjects

  2014cites this paper
• , Rajnish Loops of HIV-1 Envelope Neutralizing Epitopes in the V 2 and V 3 Distinct Mechanisms Regulate Exposure of

  2014cites this paper
• Distinct Mechanisms Regulate Exposure of Neutralizing Epitopes in the V2 and V3 Loops of HIV-1 Envelope

  2014cites this paper
• The Ontogeny of Mucosal and Systemic Antibody Responses to HIV-1 Infection

  2014cites this paper
• Antibody-Dependent, FcγRI-Mediated Neutralization of HIV-1 in TZM-bl Cells Occurs Independently of Phagocytosis

  2013cites this paper
• Designing of novel antigenic peptide cocktail for the detection of antibodies to HIV-1/2 by ELISA.

  2013cites this paper
• HIV-1-Susceptible Cells: A New Way to Expressed on the Surface of Turns into a Neutralizing Antibody When A Nonneutralizing Anti-HIV-1 Antibody

  2013cites this paper
• Epitope Mapping of Conformational V2-specific Anti-HIV Human Monoclonal Antibodies Reveals an Immunodominant Site in V2

  2013cites this paper
• A Modern Biopharmaceutical to Treat AIDS – Challenges in Designing HIV Env Immunogens for Developing a Vaccine

  2013cites this paper
• Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

  2013cites this paper
• Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

  2013cites this paper
• Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

  2013cites this paper
• A monoclonal antibody against lymphocyte function-associated antigen-1 decreases HIV-1 replication by inducing the secretion of an antiviral soluble factor

  2013cites this paper
• Structurally Conserved Binding Sites of Hemagglutinin as Targets for Influenza Drug and Vaccine Development

  2013cites this paper
• Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

  2012cites this paper
• Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors

  2012cites this paper
• Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum

  2012cites this paper
• Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

  2012cites this paper
• Designing Immunogens for Vaccine Development in Reference to HIV

  2011cites this paper
• Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection

  2011cites this paper
• The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcγRI-dependent manner

  2011cites this paper
• HIV-1 Glycoprotein Immunogenicity

  2011cites this paper
• Innovative bioinformatic approaches for developing peptide‐based vaccines against hypervariable viruses

  2011cites this paper
• The Importance of Antibody Isotype in HIV-1 Virus Capture Assay and in TZM-bl Neutralization

  2010cites this paper
• Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis

  2010cites this paper
• Nonneutralizing HIV-1 gp41 Envelope Cluster II Human Monoclonal Antibodies Show Polyreactivity for Binding to Phospholipids and Protein Autoantigens

  2010cites this paper
• Strategies for eliciting HIV-1 inhibitory antibodies

  2010cites this paper
• Anti-gp41 Antibodies Cloned from HIV-Infected Patients with Broadly Neutralizing Serologic Activity

  2010cites this paper
• In-Solution Virus Capture Assay Helps Deconstruct Heterogeneous Antibody Recognition of Human Immunodeficiency Virus Type 1

  2010cites this paper
• The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies.

  2010cites this paper
• Subtle Mimicry of HLA by HIV-1 GP120 – A Role for Anti HLA Antibodies?

  2010cites this paper
• Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies

  2010cites this paper
• Quaternary Epitope Specificities of Anti-HIV-1 Neutralizing Antibodies Generated in Rhesus Macaques Infected by the Simian/Human Immunodeficiency Virus SHIVSF162P4

  2010cites this paper
• Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins

  2009cites this paper
• Structure and function of HIV-1 CRF01_AE envelope proteins from blood and genital fluid isolates.

  2009cites this paper
• Characterisation of llama antibody fragments able to act as HIV-1 entry inhibitors

  2009cites this paper
• PROTEINS FROM BLOOD AND GENITAL FLUID ISOLATES

  2009cites this paper
• Induction of Broad Cross-Subtype-Specific HIV-1 Immune Responses by a Novel Multivalent HIV-1 Peptide Vaccine in Cynomolgus Macaques

  2008cites this paper
• A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils

  2008cites this paper
• Correlates of antibody-mediated protection against HIV infection

  2008cites this paper
• Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

  2008cites this paper
• Neutralization Patterns and Evolution of Sequential HIV Type 1 Envelope Sequences in HIV Type 1 Subtype B-Infected Drug-Naive Individuals

  2008cites this paper
• Multivalent HIV-1 Peptide Vaccine in HIV-1 Immune Responses by a Novel Induction of Broad Cross-Subtype-Specific

  2008cites this paper
• Induktion neutralisierender Antikörper gegen transmembrane Hüllproteine von Retroviren

  2008cites this paper
• Humoral immunity to HIV-1: neutralisation and antibody effector functions.

  2008cites this paper
• Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.

  2008influential citation
• HLA Homology within the C5 Domain Promotes Peptide Binding by HIV Type 1 gp120

  2008cites this paper
• Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.

  2008cites this paper
• HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies.

  2008cites this paper
• In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

  2008cites this paper
• A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

  2008cites this paper
• Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein.

  2007cites this paper
• HIV-1 neutralization: mechanisms and relevance to vaccine design.

  2007cites this paper
• “Unconventional” neutralizing activity of antibodies against HIV

  2007cites this paper
• Viral peptide immunogens: current challenges and opportunities

  2007cites this paper
• Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1

  2006cites this paper
• The role of neutralizing antibodies in HIV infection.

  2006cites this paper
• A conserved molecular action of native and recombinant Epap-1 in inhibition of HIV-1 gp120 mediated viral entry.

  2006cites this paper
• Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection

  2006cites this paper
• Production and Characterization of High-Affinity Human Monoclonal Antibodies to Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in a Mouse Model Expressing Human Immunoglobulins

  2006cites this paper
• Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins

  2006cites this paper
• The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.

  2005cites this paper
• The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.

  2005cites this paper